Welcome to our dedicated page for SANGAMO THERAPEUTICS news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on SANGAMO THERAPEUTICS stock.
Sangamo Therapeutics reports developments in genomic medicine, with a pipeline centered on neurological diseases, Fabry disease gene therapy, zinc finger epigenetic regulation, capsid discovery and modular integrase technology. Company updates commonly cover clinical and nonclinical data presentations, regulatory submissions for isaralgagene civaparvovec, or ST-920, in Fabry disease, and neurology programs such as small fiber neuropathy and chronic neuropathic pain.
Recurring news also includes financial results, earnings calls, collaboration and licensing activity around neurotropic capsids, and public-company matters affecting SGMO common stock. Listing-status announcements, including Nasdaq compliance and OTCQB quotation matters, form part of the company's corporate-status coverage alongside pipeline and technology updates.
In the PR, Sangamo Therapeutics reported recent business highlights, including raising $24 million in gross proceeds, progress in neurology pipeline, completion of dosing in Phase 1/2 STAAR study for Fabry disease, and ongoing discussions with potential Fabry collaboration partners. Pfizer anticipates BLA and MAA submissions for Hemophilia A collaboration in early 2025. Financially, Sangamo reported a net loss of $49.1 million in Q1 2024 compared to a net income of $21.1 million in Q1 2023, with revenues decreasing to $0.5 million from $158.0 million in the same period in 2023. The non-GAAP total operating expenses decreased to $43.6 million in Q1 2024 from $69.5 million in Q1 2023. Cash and cash equivalents were $54.4 million as of March 31, 2024.
Sangamo Therapeutics, Inc. presented pre-clinical data on their innovative Modular Integrase (MINT) technology, aimed at large-scale genome editing. The MINT platform utilizes Bxb1 to integrate large DNA sequences into the genome with potential applications in treating patients with unique mutations. The technology is designed to simplify manufacturing, reduce translocation risk, and enable targeted integration without the need for additional genome editing tools. The company views the MINT platform as a valuable tool for neurology-focused indications and potential collaborations in human disease and agricultural biotech.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) has announced the release of its first quarter 2024 financial results on Thursday, May 9, 2024. The company will hold a conference call at 4:30 p.m. Eastern on the same day to discuss financial results and provide business updates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.